Axsome Wins FDA Approval for First Non-Antipsychotic Alzheimer’s Agitation Treatment

Axsome Therapeutics (NASDAQ: AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease. This marks the first non-antipsychotic drug to be cleared for this indication, representing a significant advancement in neuropsychiatric treatment options.

Major Market Opportunity and Stock Reaction

Analysts at William Blair estimate that peak sales for Auvelity in the Alzheimer’s disease agitation indication could exceed $2.1 billion. Axsome shares surged nearly 13% on Thursday following the approval announcement, closing at $207.75. The approval addresses a large underserved patient population, as agitation affects up to 76% of Alzheimer’s patients in a U.S. population exceeding 7 million Americans.

Clinical Trial Results Support Approval

The approval was based on the Phase 3 ADVANCE-1 and ACCORD-2 clinical trials. In ADVANCE-1, Auvelity demonstrated statistically significant improvement over placebo in reducing agitation symptoms as measured by the Cohen-Mansfield Agitation Inventory at week five. Furthermore, a significantly greater proportion of treated patients were rated by clinicians as at least minimally improved on the modified Alzheimer’s Disease Cooperative Study–Clinical Global Impression of Change.

Long-Term Efficacy Demonstrated

In the ACCORD-2 study, a long-term, double-blind, randomized withdrawal trial, patients who continued Auvelity had a significantly longer time to relapse of agitation symptoms compared to those who switched to placebo. This finding supports the durability of the treatment effect over extended periods. Additionally, the drug exhibited a strong safety and tolerability profile with low discontinuation rates due to adverse effects, comparable to placebo.

Novel Mechanism of Action

Auvelity is described as a first-in-class oral therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. The medication combines two components: dextromethorphan, which modulates NMDA and sigma-1 receptors, and bupropion, which increases dextromethorphan blood levels by inhibiting the cytochrome P450 2D6 enzyme. While the precise mechanism of action in Alzheimer’s agitation remains under investigation, the dual-receptor approach represents a novel treatment strategy.

Clinical Significance and Patient Impact

Agitation in Alzheimer’s disease is associated with accelerated cognitive decline, increased risk of institutionalization, and higher mortality rates. This approval represents the second neuropsychiatric indication for which Auvelity has received FDA Breakthrough Therapy designation and Priority Review. Auvelity was initially approved in 2022 for major depressive disorder in adults, and more than 300,000 patients have been treated with the medication in clinical trials and real-world settings.